Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.01 USD
−198.13 M USD
0.00 USD
46.57 M
About Prime Medicine, Inc.
Sector
Industry
CEO
Keith M. Gottesdiener
Website
Headquarters
Cambridge
Founded
2019
FIGI
BBG011RT3R55
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PRME is 3.20 USD — it has decreased by −0.67% in the past 24 hours. Watch Prime Medicine, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Prime Medicine, Inc. stocks are traded under the ticker PRME.
PRME stock has fallen by −25.75% compared to the previous week, the month change is a −31.09% fall, over the last year Prime Medicine, Inc. has showed a −53.82% decrease.
We've gathered analysts' opinions on Prime Medicine, Inc. future price: according to them, PRME price has a max estimate of 19.00 USD and a min estimate of 5.00 USD. Watch PRME chart and read a more detailed Prime Medicine, Inc. stock forecast: see what analysts think of Prime Medicine, Inc. and suggest that you do with its stocks.
PRME reached its all-time high on Nov 14, 2022 with the price of 21.73 USD, and its all-time low was 3.28 USD and was reached on Oct 2, 2024. View more price dynamics on PRME chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PRME stock is 11.71% volatile and has beta coefficient of 2.71. Track Prime Medicine, Inc. stock price on the chart and check out the list of the most volatile stocks — is Prime Medicine, Inc. there?
Today Prime Medicine, Inc. has the market capitalization of 356.49 M, it has decreased by −11.21% over the last week.
Yes, you can track Prime Medicine, Inc. financials in yearly and quarterly reports right on TradingView.
Prime Medicine, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
PRME earnings for the last quarter are −0.44 USD per share, whereas the estimation was −0.39 USD resulting in a −14.19% surprise. The estimated earnings for the next quarter are −0.36 USD per share. See more details about Prime Medicine, Inc. earnings.
Prime Medicine, Inc. revenue for the last quarter amounts to 200.00 K USD, despite the estimated figure of 7.09 M USD. In the next quarter, revenue is expected to reach 9.75 M USD.
PRME net income for the last quarter is −52.52 M USD, while the quarter before that showed −55.33 M USD of net income which accounts for 5.08% change. Track more Prime Medicine, Inc. financial stats to get the full picture.
No, PRME doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 234.00 employees. See our rating of the largest employees — is Prime Medicine, Inc. on this list?
Like other stocks, PRME shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Prime Medicine, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Prime Medicine, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Prime Medicine, Inc. stock shows the sell signal. See more of Prime Medicine, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.